Video
Dr. Scarlett Gomez discusses prostate genomic testing in a world of precision medicine
Author(s):
Video Player is loading.
In this video, Scarlett Gomez, MD, PhD, discusses the background and findings of the study, “Active surveillance for watchful waiting in clinically low-risk prostate cancer patients in the SEER database with and without an Oncotype DX genomic prostate score assay,” presented at the 2021 American Urological Association Annual Meeting. Gomez is a professor in the department of epidemiology and biostatistics at the University of California, San Francisco.
Related Videos
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Related Content
